TY - JOUR
AB - PharmacoEconomics & Outcomes News 594 - 9 Jan 2010 Cotrimoxazole defeats HAART in Eastern Uganda In Eastern Uganda, highly active antiretroviral therapy (HAART) is less cost effective than many HIV prevention and care interventions, including cotrimoxazole [trimethoprim/sulfamethoxazole] prophylaxis, according to a recent study. Researchers developed a deterministic cost- effectiveness model based largely on a 2-year prospective study in which cotrimoxazole was provided to HIV-positive participants at home in Eastern Uganda with or without HAART. HAART consisted of stavudine, lamivudine and either nevirapine or, in patients with active tuberculosis, efavirenz. Selected costs and outcomes were projected over a 15-year time horizon, with the remainder calculated for the 2-year prospective study. Costs were expressed in 2004 US dollars from a societal perspective. HAART was associated with 6861 fewer lifetime DALYs and an 87% reduction in mortality when compared to cotrimoxazole alone. For the first two years of the programme, the incremental cost of HAART was $1.39 million per 1000 patients, though this was projected to rise to $4.10 million, primarily due to individuals living longer lives. Once other costs and savings had been taken into account, HAART in the Home-based AIDS Care programme was calculated to carry an incremental net cost 
TI - Cotrimoxazole defeats HAART in Eastern Uganda
JF - PharmacoEconomics & Outcomes News
DO - 10.2165/00151234-201005940-00022
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/cotrimoxazole-defeats-haart-in-eastern-uganda-wBHdooL0Zv
SP - 7
EP - 7
VL - 594
IS - 1
DP - DeepDyve
ER -